Priothera Appoints Dr. Jens Hasskarl to Lead Clinical Development
Company - People | May 08, 2025 | Fountain Healthcare Partners L
Priothera Ltd., a late-stage biopharmaceutical company, has appointed Dr. Jens Hasskarl as its new Chief Medical Officer (CMO). With extensive experience in clinical development, Dr. Hasskarl will lead Priothera's global Phase 3 clinical trial, MO-TRANS, which investigates mocravimod as an adjunctive treatment for acute myeloid leukemia (AML). Mocravimod, an S1P receptor modulator, aims to enhance the efficacy of allogeneic hematopoietic cell transplantations while minimizing complications. This strategic appointment is part of Priothera’s efforts to advance their promising therapeutic innovations in hematology. Priothera is supported by notable investors such as Fountain Healthcare Partners and is based in Dublin, with operations in France.
Sectors
- Biopharmaceuticals
- Healthcare and Life Sciences
Geography
- Ireland – Priothera is headquartered in Dublin, Ireland.
- France – Priothera operates in France, indicating its operational geography.
Industry
- Biopharmaceuticals – Priothera is a late-stage biopharmaceutical company developing innovative treatments for hematologic cancers.
- Healthcare and Life Sciences – The industry is relevant as it encompasses the development and commercialization of therapies for diseases such as acute myeloid leukemia (AML), in which mocravimod is involved.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Priothera Ltd. | Target Company | Company | A biopharmaceutical company developing mocravimod for blood cancers. |
| Dr. Jens Hasskarl | Chief Medical Officer | Person | Newly appointed CMO at Priothera, leading the Phase 3 clinical trial of mocravimod. |
| Fountain Healthcare Partners | Investor | Company | A leading investor backing Priothera. |